Received: 7 June 2020
Accepted: 15 June 2021
First Online: 3 July 2021
: The REACH-project on which this study was based, has been approved by the institutional review board of the University Medical Center Utrecht. The board waived the need for informed consent. No administrative permissions were required to access the raw data. The collected data was anonymised before its use.
: Not applicable.
: Dr. Arends reports fees paid the institution from Abbvie, BMS, Gilead, Janssen, MSD and ViiV and research grants from Abbvie and BMS, outside the submitted work. Dr. Hoepelman reports personal fees from Abbvie, BMS, Gilead and Janssen. All other authors declare that they have no competing interest with respect to the presented work.